EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Present and Future Post-marketing Drug Safety Assessment in Japan: A PMDA Perspective

Takashi Waki, Shinya Watanabe, Takashi Ando, Kazuhiro Kajiyama, Koichi Fukuda, Eiko Iwasa, Yukari Iwasaki, Masao Iwagami, Taihei Tanaka, Daisuke Maeda, Yoshiaki Uyama

Therapeutic Innovation & Regulatory Science · 2026-07 · 60 (4) · 938-940

DOI: 10.1007/s43441-026-00964-6 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutic Innovation & Regulatory Science, online erschienen am 24.04.2026. Verfasst von Takashi Waki und 10 weiteren Autor:innen. Beteiligte Einrichtung: Office of Pharmacovigilance I, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan. Hauptthemen laut MEDLINE: Product Surveillance, Postmarketing, Pharmacovigilance, Drug-Related Side Effects and Adverse Reactions. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

For pharmacovigilance, the Pharmaceuticals and Medical Devices Agency in Japan has utilized real world data (RWD) from multiple sources, including individual case safety reports, and medical information databases that capture routinely collected data from clinical practice. These RWD have their own characteristics with advantages and disadvantages. In this commentary, we describe current and future direction of post-marketing drug safety assessment in Japan.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Product Surveillance, PostmarketingPharmacovigilanceDrug-Related Side Effects and Adverse ReactionsJapanHumansAdverse Drug Reaction Reporting Systems

Stichwörter der Autor:innen

Artificial intelligenceDrug safetyIndividual case safety reportsNew methods and technologyPharmacoepidemiologyPharmacovigilanceReal-world dataRegulatory decision

Autor:innen und Institutionen

  • Office of Pharmacovigilance I, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.
  • Office of Pharmacovigilance II, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.
  • Office of Regulatory Science Research, Center for Regulatory Science, Pharmaceuticals and Medical Devices Agency, Tokyo, Japan.
  • Center for Regulatory Science, Pharmaceuticals and Medical Devices Agency, 3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo, 100-0013, Japan. uyama-yoshiaki@pmda.go.jp.

Zitieren

APA

Waki, T., Watanabe, S., Ando, T., Kajiyama, K., Fukuda, K., Iwasa, E., Iwasaki, Y., Iwagami, M., Tanaka, T., Maeda, D., & Uyama, Y. (2026). Present and Future Post-marketing Drug Safety Assessment in Japan: A PMDA Perspective. Therapeutic Innovation & Regulatory Science, 60(4), 938-940. https://doi.org/10.1007/s43441-026-00964-6

Vancouver

Waki T, Watanabe S, Ando T, Kajiyama K, Fukuda K, Iwasa E, et al. Present and Future Post-marketing Drug Safety Assessment in Japan: A PMDA Perspective. Therapeutic Innovation & Regulatory Science. 2026;60(4):938-940. doi:10.1007/s43441-026-00964-6

BibTeX
@article{Waki2026,
  author = {Waki, Takashi and Watanabe, Shinya and Ando, Takashi and Kajiyama, Kazuhiro and Fukuda, Koichi and Iwasa, Eiko and Iwasaki, Yukari and Iwagami, Masao and Tanaka, Taihei and Maeda, Daisuke and Uyama, Yoshiaki},
  title = {Present and Future Post-marketing Drug Safety Assessment in Japan: A PMDA Perspective},
  journal = {Therapeutic Innovation & Regulatory Science},
  year = {2026},
  volume = {60},
  number = {4},
  pages = {938--940},
  doi = {10.1007/s43441-026-00964-6}
}
Kostenlos starten →